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Introduction {#sec1}
============

The control of asymmetric versus symmetric cell division in stem and progenitor cells balances self-renewal and differentiation to mediate tissue homeostasis and repair and involves key proteins that control cell polarity. In the case of excess symmetric division, too many stem-cell-like daughter cells are generated that can lead to tumor initiation and growth. Conversely, excess asymmetric cell division can severely limit the number of cells available for homeostasis and repair ([@bib19], [@bib24]). The Notch pathway has been implicated in controlling stem cell self-renewal in a number of different contexts ([@bib22]). However, how cell polarity, asymmetric cell division, and the activation of determinants ultimately impinges upon the control of stem cell expansion and maintenance is not fully understood. In this study, we examine the role of an atypical protein kinase C (aPKC), PRKCi, in stem cell self-renewal and, in particular, determine whether PRKCi acts via the Notch pathway.

PKCs are serine-threonine kinases that control many basic cellular processes and are typically classified into three subgroups---conventional, novel, and the aPKCs *iota* and *zeta*, which, in contrast to the others, are not activated by diacylglyceride or calcium. The aPKC proteins are best known for being central components of an evolutionarily conserved Par3-Par6-aPKC trimeric complex that controls cell polarity in *C. elegans*, *Drosophila*, *Xenopus,* zebrafish, and mammalian cells ([@bib52]).

Before Notch influences stem cell self-renewal, the regulation of cell polarity, asymmetric versus symmetric cell division, and the segregation of cell fate determinants such as NUMB may first be required ([@bib26]). For example, mutational analysis in *Drosophila* has demonstrated that the aPKC-containing trimeric complex is required for maintaining polarity and for mediating asymmetric cell division during neurogenesis via activation and segregation of NUMB ([@bib58]). NUMB then functions as a cell fate determinant by inhibiting Notch signaling and preventing self-renewal ([@bib56]). In mammals, the PAR3-PAR6-aPKC complex also can bind and phosphorylate NUMB in epithelial cells and can regulate the unequal distribution of Numb during asymmetric cell division ([@bib48]). During mammalian neurogenesis, asymmetric division is also thought to involve the PAR3-PAR6-aPKC complex, NUMB segregation, and NOTCH activation ([@bib6]).

Mice deficient in *Prkcz* are grossly normal, with mild defects in secondary lymphoid organs ([@bib28]). In contrast, deficiency of the *Prkci* isozyme results in early embryonic lethality at embryonic day (E)9.5 ([@bib46], [@bib49]). A few studies have investigated the conditional inactivation of *Prkci*; however, no dramatic changes in progenitor generation were detected in hematopoietic stem cells (HSCs) or the brain ([@bib23], [@bib47]), although one study found evidence of a role for *Prkci* in controlling asymmetric cell division in the skin ([@bib35]). Analysis may be complicated by functional redundancy between the iota and zeta isoforms and/or because further studies perturbing aPKCs in specific cell lineages and/or at specific developmental stages are needed. Therefore, a complete picture for the requirement of aPKCs at different stages of mammalian development has not yet emerged.

Here, we investigate the requirement of *Prkci* in mouse cells using an in vitro system that bypasses early embryonic lethality. Embryonic stem (ES) cells are used to make embryoid bodies (EBs) that develop like the early post-implantation embryo in terms of lineage specification and morphology and can also be maintained in culture long enough to observe advanced stages of cellular differentiation ([@bib11]). Using this approach, we provide genetic evidence that inactivation of *Prkci* signaling leads to enhanced generation of pluripotent cells and some types of multipotent stem cells, including cells with primordial germ cell (PGC) characteristics. In addition, we provide evidence that aPKCs ultimately regulate stem cell fate via the Notch pathway.

Results {#sec2}
=======

*Prkci*^*−/−*^ Cultures Have More Pluripotent Cells Even under Differentiation Conditions {#sec2.1}
-----------------------------------------------------------------------------------------

First, we compared *Prkci* null EB development to that of *Prkci*^*−/−*^ embryos. Consistent with another null allele ([@bib46]), both null embryos and EBs fail to properly cavitate ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The failure to cavitate is unlikely to be due to the inability to form one of the three germ layers, as null EBs express germ-layer-specific genes ([Figure S1](#mmc1){ref-type="supplementary-material"}E). A failure of cavitation could alternatively be caused by an accumulation of pluripotent cells. For example, EBs generated from *Timeless* knockdown cells do not cavitate and contain large numbers of OCT4-expressing cells ([@bib37]). In addition, EBs generated with *Prkcz* isoform knockdown cells contain OCT4+ cells under differentiation conditions ([@bib12], [@bib42]). Thus, we first evaluated ES colony differentiation by alkaline phosphatase (AP) staining. After 4 days without leukemia inhibitory factor (LIF), *Prkci*^*−/−*^ ES cell colonies retained crisp boundaries and strong AP staining. In contrast, *Prkci*^*+/−*^ colonies had uneven colony boundaries with diffuse AP staining ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1F′′). To definitively detect pluripotent cells, day-12 EBs were assayed for OCT4 and E-CADHERIN (E-CAD) protein expression. *Prkci*^*+/−*^ EBs had very few OCT4/E-CAD double-positive cells ([Figure 1](#fig1){ref-type="fig"}A); however, null EBs contained large clusters of OCT4/E-CAD double-positive cells, concentrated in a peripheral zone ([Figure 1](#fig1){ref-type="fig"}A′). By examining adjacent sections, we found that OCT4+ cells could also be positive for stage-specific embryonic antigen 1 (SSEA1) ([Figures 1](#fig1){ref-type="fig"}B and 1B′). Quantification by fluorescence-activated cell sorting (FACS) analysis showed that day-12 *Prkci*^*−/−*^ EBs had more OCT4+ and SSEA1+ cells than *Prkci*^*+/−*^ EBs ([Figure 1](#fig1){ref-type="fig"}C). We did not find any difference between heterozygous and wild-type cells with respect to the number of OCT4+ or SSEA1+ cells or in their levels of expression for *Oct4*, *Nanog*, and *Sox2* ([Figures S1](#mmc1){ref-type="supplementary-material"}I, S1I′ and S1J). However, we did find that *Oct4*, *Nanog*, and *Sox2* were highly upregulated in OCT4+ null cells ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Thus, together, these data indicate that *Prkci*^*−/−*^ EBs contain large numbers of pluripotent stem cells, despite being cultured under differentiation conditions.

Functional Pluripotency Tests {#sec2.2}
-----------------------------

If primary EBs have a pluripotent population with the capacity to undergo self-renewal, they can easily form secondary EBs ([@bib37]). Using this assay, we found that more secondary EBs could be generated from *Prkci*^*−/−*^ versus *Prkci*^*+/−*^ EBs, especially at days 6, 10, and 16; even when plated at a low density to control for aggregation ([Figure S1](#mmc1){ref-type="supplementary-material"}H). To test whether SSEA1+ cells could maintain pluripotency long term, FACS-sorted *Prkci*^*−/−*^ SSEA1+ and SSEA1− cells were plated at a low density and maintained under ES cell culture conditions. SSEA1− cells were never able to form identifiable colonies and could not be maintained in culture ([Figure 1](#fig1){ref-type="fig"}D). SSEA1+ cells, however, formed many distinct colonies after 2 days of culture, and these cells could be maintained for over 27 passages ([Figures 1](#fig1){ref-type="fig"}D′, 1E′, and 1E′′). *Prkci*^*+/−*^ SSEA1+ cells formed colonies that easily differentiated at the outer edge, even in the presence of LIF ([Figure 1](#fig1){ref-type="fig"}E). In contrast *Prkci*^*−/−*^ SSEA1+ cells maintained distinct round colonies ([Figure 1](#fig1){ref-type="fig"}E′). Next, we determined whether null SSEA1+ cells expressed pluripotency and differentiation markers similarly to normal ES cells. Indeed, we found that *Oct4*, *Nanog*, and *Sox2* were upregulated in both null SSEA1+ EB cells and heterozygous ES cells. In addition, differentiated markers (*Fgf5, T*, *Wnt3*, and *Afp*) and tissue stem/progenitor cell markers (neural: *Nestin, Sox1,* and *NeuroD*; cardiac: *Nkx2-5* and *Isl1*; and hematopoietic: *Gata1* and *Hba-x*) were downregulated in both SSEA1+ cells and heterozygous ES cells ([Figure 1](#fig1){ref-type="fig"}F). SSEA1+ cells likely have a wide range of potential, since EBs generated from these cells expressed markers for all three germ layers ([Figure 1](#fig1){ref-type="fig"}G). In addition, as expected, EBs made from null SSEA1+ cells were morphologically abnormal, similar to the EBs made from unsorted *Prkci*^*−/−*^ ES cells ([Figure S1](#mmc1){ref-type="supplementary-material"}G′). Thus, taken together, several assays indicate that the OCT4 and SSEA1+ populations enriched in null EBs represent pluripotent stem cells that can self-renew and have broad differentiation capacity.

ERK1/2 Signaling during EB Development {#sec2.3}
--------------------------------------

Stem cell self-renewal has been shown to require the activation of the JAK/STAT3 and PI3K/AKT pathways and the inhibition of ERK1/2 and GSK3 pathways ([@bib27], [@bib36], [@bib45], [@bib57]). We found that both STAT3 and phosphorylated STAT3 levels were not grossly altered and that the p-STAT3/STAT3 ratio was similar between heterozygous and null ES cells and EBs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In addition we did not see any difference in AKT, pAKT, or β-CATENIN levels when comparing heterozygous to null ES cells or EBs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2C). Thus, the effects observed by the loss of *Prkci* are unlikely to be due to a significant alteration in the JAK/STAT3, PI3K/AKT, or GSK3 pathways.

Next, we investigated ERK1/2 expression and activation. Consistent with other studies showing ERK1/2 activation to be downstream of *Prkci* in some mammalian cell types ([@bib4], [@bib29]), pERK1/2 was markedly inactivated in *Prkci* null versus heterozygous ES cells. In addition, during differentiation, null EBs displayed strong pERK1/2 inhibition early (until day 6). Later, pERK1/2 was activated strongly, as the EB began differentiating ([Figures 2](#fig2){ref-type="fig"}A and 2B). By immunofluorescence, pERK1/2 was strongly enriched in the columnar epithelium of control EBs, while overall levels were much lower in *Prkci*^*−/−*^ EBs ([Figure 2](#fig2){ref-type="fig"}C). In addition, high OCT4 expression correlated with a marked inactivation of pERK1/2 ([Figure 2](#fig2){ref-type="fig"}C). Next, we examined *Prkci*^*−/−*^ SSEA1+ cells by western blot. We found that SSEA1+ cells isolated from day-12 null EBs had pSTAT3 expression levels similar to whole EBs, while pERK1/2 levels were low ([Figure 2](#fig2){ref-type="fig"}D). Thus, these experiments indicate that the higher numbers of pluripotent cells in null EBs correlate with a strong inactivation of ERK1/2.

Neural Stem Cell Fate Is Favored in *Prkci*^*−/−*^ EBs {#sec2.4}
------------------------------------------------------

It is well known that ERK/MEK inhibition is not sufficient for pluripotent stem cell maintenance ([@bib61]); thus, other pathways are likely involved. Therefore, we used a TaqMan Mouse Stem Cell Pluripotency Panel (\#4385363) on an OpenArray platform to investigate the mechanism of *Prkci* action. Day 13 and day 20 *Prkci*^*−/−*^ EBs expressed high levels of pluripotency and stemness markers versus heterozygous EBs, including *Oct4*, *Utf1*, *Nodal*, *Xist*, *Fgf4*, *Gal*, *Lefty1*, and *Lefty2*. However, interestingly, EBs also expressed markers for differentiated cell types and tissue stem cells, including *Sst*, *Syp*, and *Sycp3* (neural-related genes), *Isl1* (cardiac progenitor marker), *Hba-x*, and *Cd34* (hematopoietic markers). Based on this first-pass test, we sought to determine whether loss of *Prkci* might favor the generation of neural, cardiac, and hematopoietic cell types and/or their progenitors.

First, we found that null EBs contained many more NESTIN- and PAX6-positive cells than heterozygous EBs ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) (neural stem and progenitor markers) ([@bib43], [@bib53]). In addition, quantification of PAX6 immunofluorescence (easier to quantify because of its nuclear localization) using a pixel count method ([@bib16]) revealed more abundant PAX6+ cells in null EBs versus heterozygous EBs. This difference was no longer evident at day 16, presumably because most of the new neural progenitors had differentiated ([Figure 3](#fig3){ref-type="fig"}D). Indeed, differentiated neuronal markers MAP2 and TUJ1 could be expressed in null cell cultures ([Figures 3](#fig3){ref-type="fig"}C and 3C′). Retinoic acid (RA) treatment both in EBs and ES cells promotes neurogenesis ([@bib59]). We found that, even under RA induction, null cultures contained a larger population of NESTIN+ and a smaller population of TUJ1+ cells when compared to heterozygous cultures ([Figures 3](#fig3){ref-type="fig"}E and 3F). Again, null neural progenitors were capable of undergoing some differentiation, since we could find cells expressing NEUROD, NEUN, and MAP2 ([Figures 3](#fig3){ref-type="fig"}F′--3F′′′). We also assessed neurogenesis in monolayer culture, using media that promotes neural stem cell generation supplemented with a low concentration of RA ([@bib59]). Similar to the EB assay, we found that null ES cells generated a larger NESTIN+ and smaller TUJ1+ population compared to heterozygous ES cells ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Like in EBs, MAP2- and TUJ1-positive cells could still be found in the null cultures ([Figure S3](#mmc1){ref-type="supplementary-material"}D′). Thus, using several different neural-induction assays, we found that the absence of *Prkci* correlates with the production of more neural progenitors and that, although these cells may favor self-renewal, they are still capable of progressing toward differentiation.

The Generation of Cardiomyocyte and Erythrocyte Progenitors Is Also Favored {#sec2.5}
---------------------------------------------------------------------------

Next, we examined ISL1 expression (a cardiac stem cell marker) by immunofluorescence and found that *Prkci*^*−/−*^ EBs contained larger ISL1 clusters compared with *Prkci*^*+/−*^ EBs; this was confirmed using an image quantification assay ([Figures 4](#fig4){ref-type="fig"}A, 4A′, and 4C). Differentiated cardiac cells and ventral spinal neurons can also express ISL1 ([@bib13]); therefore, we also examined *Nkx2-5* expression, a better stem cell marker and regulator of cardiac progenitor determination ([@bib5]), by RT-PCR and immunofluorescence. In null EBs, *Nkx2-5* was upregulated ([Figure 4](#fig4){ref-type="fig"}D). In addition, in response to RA, which can promote cardiac fates in vitro ([@bib34]), cells expressing NKX2-5 were more prevalent in null versus heterozygous EBs ([Figures 4](#fig4){ref-type="fig"}B and 4B′).The abundant cardiac progenitors found in null EBs were still capable of undergoing differentiation ([Figures 4](#fig4){ref-type="fig"}E--4F′). Indeed, more cells exhibited the striated pattern characteristic of α-ACTININ in null versus heterozygous EBs with RA induction ([Figures 4](#fig4){ref-type="fig"}F and 4F′). In addition, many more *Prkci*^*−/−*^ EBs were beating after days 6 and 12 of culture ([Figure 4](#fig4){ref-type="fig"}G).

*Hba-x* expression is restricted to yolk sac blood islands and primitive erythrocyte populations ([@bib30], [@bib54]). *Cd34* is also a primitive HSC marker ([@bib51]). Next, we determined whether the elevated expression of these markers observed with OpenArray might represent higher numbers of primitive hematopoietic progenitors. Using a colony-forming assay ([@bib2]), we found that red colonies (indicative of erythrocyte differentiation; examples in [Figure 4](#fig4){ref-type="fig"}I) were produced significantly earlier and more readily from cells isolated from null versus heterozygous EBs ([Figure 4](#fig4){ref-type="fig"}H). By quantitative real-time PCR, upregulation of *Hba-x* and *Cd34* genes confirmed the OpenArray results ([Figure 4](#fig4){ref-type="fig"}J). In addition, we found *Gata1*, an erythropoiesis-specific factor, and *Epor*, an erythropoietin receptor that mediates erythroid cell proliferation and differentiation ([@bib8]), to be highly upregulated in null versus heterozygous EBs ([Figure 4](#fig4){ref-type="fig"}J). These data suggest that the loss of *Prkci* promotes the generation of primitive erythroid progenitors that can differentiate into erythrocytes.

To determine whether the aforementioned tissue stem cells identified were represented in the OCT4+ population that we described earlier, we examined the expression of PAX6, ISL1, and OCT4 in adjacent EB sections. We found that cells expressing OCT4 appeared to represent a distinct population from those expressing PAX6 and ISL1 (although some cells were PAX6 and ISL1 double-positive) ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C).

*Prkci*^*−/−*^ Cells Are More Likely to Inherit NUMB/aNOTCH1 Symmetrically {#sec2.6}
--------------------------------------------------------------------------

The enhanced production of both pluripotent and tissue stem cells suggests that the mechanism underlying the action of *Prkci* in these different contexts is fundamentally similar. Because the Notch pathway controls stem cell self-renewal in many contexts ([@bib22]), and because previous studies implicated a connection between PRKCi function and the Notch pathway ([@bib6], [@bib48]), we examined the localization and activation of a key player in the Notch pathway, NUMB, ([@bib24]). Differences in NUMB expression were first evident in whole EBs, where polarized expression was evident in the ectodermal and endodermal epithelia of heterozygous EBs, while *Prkci*^*−/−*^ EBs exhibited a more even distribution ([Figures 5](#fig5){ref-type="fig"}A--5B′). To more definitively determine the inheritance of NUMB during cell division, doublets undergoing telophase or cytokinesis were scored for symmetric (evenly distributed in both cells) or asymmetric (unequally distributed) NUMB localization (examples: [Figures 5](#fig5){ref-type="fig"}C and 5C′). In dissociated day-10 EBs, *Prkci*^*+/−*^ doublets displayed somewhat less symmetric versus asymmetric inheritance, while *Prkci*^*−/−*^ doublets exhibited nearly four times more symmetric versus asymmetric inheritance ([Figure 5](#fig5){ref-type="fig"}D). Although individual cells from null EBs that were OCT4+ or PAX6+ more likely to exhibit non-polarized NUMB distribution ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), we decided to use an assay that allowed for FACS purification, followed by the more stringent doublet assay. Therefore, we chose CD24 (heat-stable antigen; BA-1), a cell-surface marker that is highly expressed in pre-differentiated neurons and neuroblasts ([@bib41]), and tested this marker as a method to enrich for cells destined to differentiate into neurons (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). To assess NUMB localization, FACS-sorted CD24 cells isolated from the RA-treated EBs were then put in culture for 24 hr, and doublets were scored. Both *Prkci*^*−/−*^ CD24^high^ and CD24^low^ doublets exhibited more symmetric versus asymmetric NUMB localization when compared to *Prkci*^*+/−*^ doublets ([Figure 5](#fig5){ref-type="fig"}E) (\>2× more was observed for CD24^low^ doublets; 1.5 ± 0.25 \[null\] versus 0.67 ± 0.2 \[heterozygous\]). Thus, in summary, loss of *Prkci* favors the generation of cells with symmetric NUMB distribution, even during EB differentiation. In addition, in situations where neurogenesis is stimulated (RA treatment), loss of *Prkci* favors symmetric NUMB distribution in both the CD24^high/low^ subpopulations.

Because NUMB can be directly phosphorylated by aPKCs (both PRKCi and PRKCz) ([@bib48], [@bib62]), loss of *Prkci* might be expected to lead to decreased NUMB phosphorylation. Three NUMB phosphorylation sites---Ser7, Ser276, and Ser295---could be aPKC mediated ([@bib48]). By immunofluorescence, we found that one of the most well-characterized sites (Ser276), was strongly inactivated in null versus heterozygous EBs, especially in the core ([Figures 5](#fig5){ref-type="fig"}F and 5G). Western analysis also confirmed that the levels of pNUMB (Ser276) were decreased in null versus heterozygous EBs ([Figure S5](#mmc1){ref-type="supplementary-material"}F). Thus, genetic inactivation of *Prkci* leads to a marked decrease in the phosphorylation status of NUMB.

Notch pathway inhibition by NUMB has been observed in flies and mammals ([@bib3], [@bib17]). Therefore, we investigated whether reduced Numb activity in *Prkci*^*−/−*^ EBs might lead to enhanced NOTCH1 activity and the upregulation of the downstream transcriptional readouts ([@bib32]). An overall increase in NOTCH1 activation was supported by western blot analysis showing that the level of activated NOTCH1 (aNOTCH1) was strongly increased in day 6 and day 10 null versus heterozygous EBs ([Figure S5](#mmc1){ref-type="supplementary-material"}G). This was supported by immunofluorescence in EBs, where widespread strong expression of aNOTCH1 was seen in most null cells ([Figures 5](#fig5){ref-type="fig"}I and 5I′), while in heterozygous EBs, this pattern was observed only in the OCT4+ cells ([Figures 5](#fig5){ref-type="fig"}H and 5H′). To examine the localization of aNOTCH1 and to better quantify the results seen in [Figures 5](#fig5){ref-type="fig"}H and 5I, doublets from dissociated EBs were scored. As seen with NUMB localization, null doublets were more likely to have symmetric localization of aNOTCH1 in comparison to heterozygous doublets ([Figure 5](#fig5){ref-type="fig"}K; examples in [Figures 5](#fig5){ref-type="fig"}M and 5M′). In addition, both CD24^high^ and CD24^low^ doublets from RA-treated null EBs were more likely to exhibit symmetric aNOTCH1 distribution versus doublets from RA-treated heterozygous EBs ([Figure 5](#fig5){ref-type="fig"}L; 3.46 ± 0.8 \[null\] versus 0.59 ± 0.06 \[heterozygous\] in CD24^low^ doublets). In addition, by RT-PCR, the expression of Notch downstream genes *Hes1*, *Hes5*, *Hey1*, and *Hey2* was increased in null versus heterozygous EBs ([Figure S5](#mmc1){ref-type="supplementary-material"}I). Furthermore, HES5 by immunofluorescence was broadly expressed at similar levels in both null and heterozygous cells ([Figures 5](#fig5){ref-type="fig"}J and 5J′; [Figures S5](#mmc1){ref-type="supplementary-material"}H and S5H′) but more strongly expressed in null OCT4+ cells ([Figures 5](#fig5){ref-type="fig"}J and 5J′). Thus, loss of *Prkci* is associated with NOTCH1 activation, aNOTCH1 symmetric localization, and the upregulation of *Hes/Hey* downstream genes in several assays.

To determine whether Notch pathway activation is required in the absence of *Prkci*, we examined AP activity and OCT4 expression while blocking the Notch pathway using DAPT to inhibit γ-secretase ([@bib44]). DMSO-treated null ES cells stayed undifferentiated (sharp-edged colonies, strong AP staining); however, treatment of null ES cells with 3 μM DAPT led to more differentiation (AP-negative cells with cellular extensions) ([Figures 5](#fig5){ref-type="fig"}N, 5O, and [S5](#mmc1){ref-type="supplementary-material"}J). In addition, OCT4 is strongly expressed in day-4 control ES cell cultures; however, in the presence of DAPT, OCT4 expression is much decreased both in monolayer culture ([Figures 5](#fig5){ref-type="fig"}P--5R) and in null EBs (48% lower OCT4+ signal versus DMSO controls, pixel counting on EB sections; data not shown). These results support the idea that activated Notch signaling is required in the absence of *Prkci* to see enhanced pluripotency.

Taken together, the combined effects of decreased NUMB activation, favored symmetric distribution of NUMB and aNOTCH1 and increased NOTCH1 activity support a model whereby loss of *Prkci* leads to sustained generation of pluripotent and some tissue stem cell populations ([Figure 5](#fig5){ref-type="fig"}S; and see [Discussion](#sec3){ref-type="sec"}).

Additional Loss of PRKCz Activity Boosts the Number of OCT4-, SSEA1-, and STELLA-Positive Cells {#sec2.7}
-----------------------------------------------------------------------------------------------

The generation and maintenance of pluripotent stem cells from new sources or tissue stem cells for basic or translational research can be challenging, and there is need for new in vitro strategies. A PKC inhibitor (Gö6983) that inhibits PKCα, -β, -γ, -δ, and -ζ has been used to help maintain mouse and rat ES cells in the absence of LIF ([@bib12], [@bib42]). Thus, we hypothesized that treating null cells with Gö6983 might lead to better stem cell expansion compared to loss of just *Prkci*. In our hands, we found that, under differentiation conditions (no LIF), heterozygous ES cells treated with the inhibitor for 4 days still underwent differentiation ([Figure 6](#fig6){ref-type="fig"}A), while treated null ES cells largely stayed undifferentiated ([Figure 6](#fig6){ref-type="fig"}A′; [Figure S6](#mmc1){ref-type="supplementary-material"}A). Drug treatment of heterozygous EBs boosted the generation of OCT4-expressing cells ([Figure 6](#fig6){ref-type="fig"}B), while treatment of null EBs resulted in an even larger OCT4+ population ([Figure 6](#fig6){ref-type="fig"}B′). NUMB localization was also moderately affected ([Figure S6](#mmc1){ref-type="supplementary-material"}B). By cell sorting, we found that drug treatment significantly increased the percentage of OCT4+ cells in both *Prkci*^*+/−*^ and *Prkci*^*−/−*^ EBs ([Figures 6](#fig6){ref-type="fig"}C and 6C′; [Figures S6](#mmc1){ref-type="supplementary-material"}C and S6C′). Interestingly, Gö6983 treatment also boosted the generation of SSEA1+ cells in both null and heterozygous EBs ([Figures 6](#fig6){ref-type="fig"}D and 6D′; [Figures S6](#mmc1){ref-type="supplementary-material"}D and S6D′).

SSEA1 is expressed in BLIMP1-positive PGCs derived from mouse epiblast stem cells ([@bib21]). Also, PGC-like cells can be derived from isolated SSEA1+/OCT4+ EB cells ([@bib18]). Therefore, we speculated that the increase in SSEA1 and OCT4 due to Gö6983 treatment could represent an increase in the generation of PGC-like cells instead of undifferentiated ES cells. Therefore, we examined the expression of STELLA (a PGC marker). As expected, heterozygous EBs contain small clusters of STELLA+ cells similar to EBs made of wild-type cells ([Figure 6](#fig6){ref-type="fig"}E) ([@bib38]). The addition of Gö6983 to *Prkci*^*+/−*^ EBs induced a modest increase in the number of STELLA+ cells present in the clusters ([Figure 6](#fig6){ref-type="fig"}F). Without drug treatment, null EBs contained more clusters, and the clusters contained more STELLA+ cells when compared to heterozygous EBs ([Figures 6](#fig6){ref-type="fig"}E and 6G). Interestingly, when *Prkci*^*−/−*^ EBs were treated with Gö6983, the generation of STELLA+ cells was strongly enhanced ([Figure 6](#fig6){ref-type="fig"}G versus [Figure 6](#fig6){ref-type="fig"}H). Because undifferentiated ES cells can still express STELLA ([@bib38]), we co-stained EBs for VASA (a more differentiated PGC marker). We found many cells that were double positive (a little less than half) ([Figure 6](#fig6){ref-type="fig"}K) but also cells that expressed VASA only and STELLA only (∼2× more than VASA only) ([Figures 6](#fig6){ref-type="fig"}I--6K, red/green arrows). Therefore, the combined effect of loss of *Prkci* and PKC inhibition via Gö6983 treatment leads to the production of STELLA and VASA+ PGC-like cells.

Next, we examined whether the more specific aPKC inhibitor, ZIP, a myristolated aPKC pseudosubstrate with competitive binding to p62, had similar effects ([@bib40], [@bib55], [@bib60]). We found that both heterozygous and null EBs treated with ZIP contained more OCT4+ cells compared to un-treated EBs ([Figures 6](#fig6){ref-type="fig"}L--6O). In addition, like Gö6983, ZIP treatment resulted in a modest increase in the percentage of SSEA1+ cells found in heterozygous EBs and a strong increase in the percentage of SSEA1+ cells in null EBs ([Figures S6](#mmc1){ref-type="supplementary-material"}E--S6F′). Furthermore, like Gö6983, both STELLA+ and VASA+ populations were increased with ZIP treatment ([Figure 6](#fig6){ref-type="fig"}P). Thus, both pluripotent and PGC-like cells can be abundantly generated with Gö6983 or ZIP treatment, suggesting that strategies that inhibit both PRKCi and/or PRKCz may be useful to maintain stem cell self-renewal and/or generate abundant PGC-like cells.

Discussion {#sec3}
==========

In this report, we suggest that *Prkci* controls the balance between stem cell expansion and differentiation/maintenance by regulating the activation of NUMB, NOTCH1, and *Hes* /*Hey* downstream effector genes. In the absence of *Prkci,* the pluripotent cell fate is favored, even without LIF, yet cells still retain a broad capacity to differentiate. In addition, loss of *Prkci* results in enhanced generation of tissue progenitors such as neural stem cells and cardiomyocyte and erythrocyte progenitors. In contrast to recent findings on *Prkcz* ([@bib12]), loss of *Prkci* does not appear to influence STAT3, AKT, or GSK3 signaling but results in decreased ERK1/2 activation. We hypothesize that, in the absence of *Prkci*, although ERK1/2 inhibition may be involved, it is the decreased NUMB phosphorylation and increased NOTCH1 activation that promotes stem and progenitor cell fate. Thus, we conclude that PRKCi, a protein known to be required for cell polarity, also plays an essential role in controlling stem cell fate and generation via regulating NOTCH1 activation.

Notch Activation Drives the Decision to Self-Renew versus Differentiate {#sec3.1}
-----------------------------------------------------------------------

Notch plays an important role in balancing stem cell self-renewal and differentiation in a variety of stem cell types and may be one of the key downstream effectors of *Prkci* signaling. Sustained Notch1 activity in embryonic neural progenitors has been shown to maintain their undifferentiated state ([@bib25]). Similarly, sustained constitutive activation of NOTCH1 stimulates the proliferation of immature cardiomyocytes in the rat myocardium ([@bib9]). In HSCs, overexpression of constitutively active NOTCH1 in hematopoietic progenitors and stem cells supports both primitive and definitive HSC self-renewal ([@bib50]). Together, these studies suggest that activation and/or sustained Notch signaling can lead to an increase in certain tissue stem cell populations. Thus, a working model for how tissue stem cell populations are favored in the absence of *Prkci* involves a sequence of events that ultimately leads to Notch activation. Recent studies have shown that aPKCs can be found in a complex with NUMB in both *Drosophila* and mammalian cells ([@bib48], [@bib62]); hence, in our working model ([Figure 5](#fig5){ref-type="fig"}S), we propose that the localization and phosphorylation of NUMB is highly dependent on the activity of PRKCi. When *Prkci* is downregulated or absent (as shown here), cell polarity is not promoted, leading to diffuse distribution and decreased phosphorylation of NUMB. Without active NUMB, NOTCH1 activation is enhanced, *Hes/Hey* genes are upregulated, and stem/progenitor fate generation is favored. To initiate differentiation, polarization could be stochastically determined but could also be dependent on external cues such as the presentation of certain ligands or extracellular matrix (ECM) proteins ([@bib20]). When PRKCi is active and the cell becomes polarized, a trimeric complex is formed with PRKCi, PAR3, and PAR6. Numb is then recruited and phosphorylated, leading to Notch inactivation, the repression of downstream *Hes/Hey* genes, and differentiation is favored (see [Figure 5](#fig5){ref-type="fig"}S). Support for this working model comes from studies in *Drosophila* showing that the aPKC complex is essential for Numb activation and asymmetric localization ([@bib26], [@bib48], [@bib56]). Additional studies on mouse neural progenitors show that regulating Numb localization and Notch activation is critical for maintaining the proper number of stem/progenitor cells in balance with differentiation ([@bib6]). Thus, an important function for PRKCi may be to regulate the switch between symmetric expansion of stem/progenitor cells to an asymmetric differentiation/maintenance phase. In situations of low or absent PRKCi, we propose that the expansion phase is favored. Thus, temporarily blocking either, or both, of the aPKC isozymes may be a powerful approach for expanding specific stem/progenitor populations for use in basic research or for therapeutic applications.

These studies, together with data presented here, provide genetic evidence that evolutionarily conserved polarity pathways may play a central role in NOTCH1 activation and stem cell self-renewal in mammals. Further genetic studies using *Cre* transgenes that are specific for progenitors in the neural plate, primitive erythrocytes, cardiomyocytes, and other progenitors to ablate aPKC function will be needed to determine how generally this mechanism is used in diverse tissues.

Although we do not see changes in the activation status of the STAT3, AKT, or GSK3 pathway, loss of *Prkci* results in an inhibition of ERK1/2 ([Figures 2](#fig2){ref-type="fig"}A and 2B). This result is consistent with the findings that ERK1/2 inhibition is both correlated with and directly increases ES cell self-renewal ([@bib7]). Modulation of ERK1/2 activity by *Prkci* has been observed in cancer cells and chondrocytes ([@bib29], [@bib33]). Although it is not clear whether a direct interaction exists between *Prkci* and ERK1/2, *Prkcz* directly interacts with ERK1/2 in the mouse liver and in hypoxia-exposed cells ([@bib10], [@bib39]). The *Prkcz* isozyme is still expressed in *Prkci* null cells but evidently cannot sufficiently compensate and activate the pathway normally. Furthermore, knocking down *Prkcz* function in ES cells does not result in ERK1/2 inhibition, suggesting that this isozyme does not impact ERK1/2 signaling in ES cells ([@bib12]). Therefore, although PRKCi may interact with ERK1/2 and be directly required for its activation, ERK1/2 inhibition could also be a readout for cells that are more stem-like. Further studies will be needed to address this question.

Utility of Inhibiting aPKC Function {#sec3.2}
-----------------------------------

Loss of *Prkci* resulted in EBs that contained slightly more STELLA+ cells than EBs made from +/− cells. Furthermore, inhibition of both aPKC isozymes by treating *Prkci* null cells with the PKC inhibitor Gö6983 or the more specific inhibitor, ZIP, strongly promoted the generation of large clusters of STELLA+ and VASA+ cells, suggesting that inhibition of both isozymes is important for PGC progenitor expansion ([Figure 6](#fig6){ref-type="fig"}). It is unclear what the mechanism for this might be; however, one possibility is that blocking both aPKCs is necessary to promote NOTCH1 activation in PGCs or in PGC progenitor cells that may ordinarily have strong inhibitions to expansion ([@bib14]). Regardless of mechanism, the ability to generate PGC-like cells in culture is notoriously challenging, and our results provide a method for future studies on PGC specification and differentiation.

Expansion of stem/progenitor pools may not be desirable in the context of cancer. *Prkci* has been characterized as a human oncogene, a useful prognostic cancer marker, and a therapeutic target for cancer treatment. Overexpression of *Prkci* is found in epithelial cancers ([@bib15]), and *Prkci* inhibitors are being evaluated as candidate cancer therapies ([@bib1], [@bib31]). However, because our results show that *Prkci* inhibition leads to enhanced stem cell production in vitro, *Prkci* inhibitor treatment as a cancer therapy might lead to unintended consequences (tumor overgrowth), depending on the context and treatment regimen. Thus, extending our findings to human stem and cancer stem cells is needed.

In summary, here, we demonstrate that loss of *Prkci* leads to the generation of abundant pluripotent cells, even under differentiation conditions. In addition, we show that tissue stem cells such as neural stem cells, primitive erythrocytes, and cardiomyocyte progenitors can also be abundantly produced in the absence of *Prkci*. These increases in stem cell production correlate with decreased NUMB activation and symmetric NUMB localization and require Notch signaling. Further inhibition of *Prkcz* may have an additive effect and can enhance the production of PGC-like cells. Thus, *Prkci* (along with *Prkcz*) may play key roles in stem cell self-renewal and differentiation by regulating the Notch pathway. Furthermore, inhibition of *Prkci* and or *Prkcz* activity with specific small-molecule inhibitors might be a powerful method to boost stem cell production in the context of injury or disease.

Experimental Procedures {#sec4}
=======================

Differentiation Assays {#sec4.1}
----------------------

All animal procedures were carried out in accordance with approved Animal Care and Use Protocols at the University of Southern California. *Prkci*^*−/−*^ embryo and ES cell derivation, EB culture, and confirmation of phenotype by lentiviral transfection methods are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and [Figure S1](#mmc1){ref-type="supplementary-material"}. To assay neural differentiation, EBs were treated with 10 μM RA (Sigma; R2625-500MG) during days 2--6. To assay cardiomyoctye differentiation, day 6 and day 12 EBs were treated with 100 nM RA for 2 days. For the colony-forming assay, EBs were dissociated into single cells (0.25% collagenase type IV, GIBCO, 17104-019), resuspended in MethoCult GF M3434 (Stem Cell Technologies), and cultured for 2 weeks.

For DAPT treatment, ES cells were cultured for 24 hr without LIF, then for 4 days in 3 μM or 10 μM DAPT (Calbiochem, 565784) or carrier (DMSO). Samples were assayed by immunofluoresence or for alkaline phosphatase activity (Millipore, SCR004).

To inhibit aPKCs, ES cells were treated with 5 μM Gö6983 (Sigma), 20 μM of the pseudo-substrate ZIP (Anaspec, 63361 Myr- SIYRRGARRWRKL), or an equivalent amount of carrier (DMSO) and then used to make EBs, which were treated with 5 μM Gö6983 or 20 μM ZIP every other day. ZIP treatment did not affect *Prkcz* RNA or protein expression levels ([Figures S6](#mmc1){ref-type="supplementary-material"}G and S6H).

Immunofluorescence and sorting assays are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA Expression {#sec4.2}
--------------

### Semiquantitative {#sec4.2.1}

Total RNA (RNeasy Extraction Kit, QIAGEN) was reverse transcribed using M-MuLV Reverse Transcriptase (New England Biolabs, M0253S) with random hexamers (Invitrogen, N8080127). See [Table S2](#mmc1){ref-type="supplementary-material"} for PCR primer sequences.

### RealTime Ready {#sec4.2.2}

Total RNA was isolated with the High Pure RNA Isolation Kit (Roche) and reverse transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche). PCR was carried out using the LightCycler 480 Probes Master Mix and a LightCycler 480 RealTime Ready custom plate (Roche). Unless otherwise noted, expression was normalized to the mean expression of four reference genes (*beta-actin*, *Gapdh*, *B2m*, and *Eef1a1*).

Quantitative Analysis {#sec4.3}
---------------------

The unpaired Student's t test in Microsoft Excel was used to evaluate statistical significance. For doublet analysis, data are displayed as a ratio of symmetric versus asymmetric localization, where the value 1 represents both found equally (details in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S6, and Tables S1 and S2Document S2. Article plus Supplemental Information
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![*Prkci*^*−/−*^ EBs Contain Cells with Pluripotency Characteristics\
(A and A′) Day (d) 12 heterozygous EBs have few OCT4/E-CAD+ cells, while null EBs contain many in clusters at the EB periphery. Inset: OCT4 (nucleus)/E-CAD (cytoplasm) double-positive cells.\
(B and B′) Adjacent sections in a null EB show that OCT4+ cells are likely also SSEA1+.\
(C) Dissociated day-12 *Prkci*^*−/−*^ EBs contain five to six times more OCT4+ and approximately three times more SSEA1+ cells than heterozygous EBs (three independent experiments).\
(D and D′) After 2 days in ES cell culture, no colonies are visible in null SSEA1− cultures while present in null SSEA1+ cultures (red arrows).\
(E--E′′) SSEA1+ sorted cells can be maintained for many passages, 27+. (E) *Prkci*^*+/−*^ sorted cells make colonies with differentiated cells at the outer edges (n = 27/35). (E′) Null cells form colonies with distinct edges (n = 39/45). (E′′) The percentage of undifferentiated colonies is shown. ^∗∗∗^p \< 0.001.\
(F) Sorted null cells express stem cell and differentiation markers at similar levels to normal ES cells (versus heterozygous EBs) (three independent experiments).\
(G) EBs made from null SSEA1+ sorted cells express germ layer marker genes at the indicated days.\
Error bars indicate mean ± SEM, three independent experiments. Scale bars, 100 μm in (A, D, and E); 25 μm in (B).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![*Prkci* and Pluripotency Pathways\
(A) ERK1/2 phosphorylation (Y202/Y204) is reduced in null ES cells and early day (d)-6 null EBs compared to heterozygous EBs and strongly increased at later stages. The first lane shows ES cells activated (A) by serum treatment 1 day after serum depletion.\
(B) Quantification of pERK1/2 normalized to non-phosphorylated ERK1/2 (three independent experiments; mean ± SEM; ^∗∗^p \< 0.01).\
(C) pERK1/2 ^Y202/Y204^ is strongly expressed in the columnar epithelium of heterozygous EBs that have just cavitated. Null EBs have lower expression. OCT4 and pERK1/2 expression do not co-localize. Scale bar, 100 μm.\
(D) pERK1/2^Y202/Y204^ levels are lower in null SSEA1+ sorted cells than in heterozygous or in null day-12 EBs that have undergone further differentiation. pSTAT3 and STAT levels are unchanged.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Neural Stem Cell Populations Are Increased in Null EBs\
(A--C′) Prkci^*−/−*^ EBs (B) have more NESTIN-positive cells than Prkci^*+/−*^ EBs (A). (C and C′) MAP2 and TUJ1 are expressed in null EBs, similarly to heterozygous EBs (data not shown).\
(D) EBs were assessed for PAX6 expression, and the images were used for quantification ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). The pixel count ratio of PAX6+ cells in null EBs (green) is substantially higher than that found in heterozygous EBs (black) (three independent experiments; mean ± SEM; ^∗^p \< 0.05).\
(E--F′′′) Day 4 after RA treatment, *Prkci*^*−/−*^ EBs have more NESTIN- than TUJ1-positive neurons (E and F). However, null cells can still terminally differentiate into NEUROD-, NEUN-, and MAP2-positive cells (F′--F′′′).\
Scale bars, 25 μm in (A and C) and 50 μm in (E).\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Cardiomyocyte and Erythrocyte Progenitors Are Increased in *Prkci*^*−/−*^ EBs\
(A--F′) In (A, A′, E, and E′), *Prkci*^*−/−*^ EBs cultured without LIF have more ISL1 (cardiac progenitor marker) and α-ACTININ-positive cells compared to heterozygous EBs. (C) At day (d) 9, the pixel count ratio for ISL1 expression indicates that null EBs (green) have larger ISL1 populations than heterozygous EBs (black) (three independent experiments, n = 20 heterozygous EBs, 21 null EBs total; mean ± SEM; ^∗^p \< 0.05). In (B, B′, D, F, and F′), RA treatment induces more NKX2-5 (both nuclear and cytoplasmic) and α-ACTININ expression in null EBs. Arrows point to fibers in (F′).\
(G) Null EBs (green) generate more beating EBs with RA treatment compared to heterozygous EBs (black) (four independent experiments; mean ± SEM; ^∗^p \< 0.05, ^∗∗∗^p \< 0.001).\
(H) Dissociated null EBs of different stages (green) generate more erythrocytes in a colony-forming assay (CFU-E) (four independent experiments; mean ± SEM; ^∗∗^p \< 0.01).\
(I) Examples of red colonies.\
(J) Gene expression for primitive HSC markers is upregulated in null EBs (relative to heterozygous EBs) (three independent experiments; mean ± SEM).\
Scale bars, 50 μm in (A, B, and E); 100 μm in (F), and 25 μm in (I).\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![*Prkci*^*−/−*^ Cells Preferentially Inherit Symmetric Localization of NUMB and aNOTCH1 and Notch Signaling Is Required for Stem Cell Self-Renewal in Null Cells\
(A--B′) In (A and B), day (d)-7 heterozygous EBs have polarized NUMB localization within epithelia and strong expression in the endoderm, while null EBs have a more even distribution. (A′ and B′) Enlarged views.\
(C and C′) Asymmetric and symmetric NUMB expression examples.\
(D) Doublets from day-10 null EBs have more symmetric inheritance when compared to day-10 heterozygous doublets (three independent experiments; mean ± SEM; ^∗∗^p \< 0.01). A red line indicates a ratio of 1 (equal percent symmetric and asymmetric).\
(E) CD24^high^ null doublets exhibited more symmetric NUMB inheritance than CD24^high^ heterozygous doublets (three independent experiments; mean ± SEM; ^∗^p \< 0.05). A red line indicates where the ratio is 1.\
(F and G) Decreased pNUMB (Ser276) is evident in the core of null versus heterozygous EBs (n = 10 of each genotype).\
(H--I′) In (H and I), aNOTCH1 is strongly expressed in heterozygous EBs, including both OCT4+ and OCT4− cells, while strong aNOTCH1 expression is predominant in OCT4+ cells of null EBs (n = 10 of each genotype)). (H′ and I′) Enlarged views of boxed regions. OCT4+ cells are demarcated with dotted lines.\
(J and J′) OCT4+ cells express HES5 strongly in the nucleus (three independent experiments).\
(K) Null doublets from dissociated EBs have more symmetric aNOTCH1 inheritance compared to heterozygous doublets (three independent experiments; mean ± SEM; ^∗∗^p \< 0.01). A red line indicates where the ratio is 1.\
(L) CD24^high^*Prkci*^*−/−*^ doublets exhibit more symmetric aNOTCH1 than CD24^high^ heterozygous doublets (three independent experiments; mean ± SEM; ^∗^p \< 0.05). A red line indicates where the ratio is 1.\
(M and M′) Examples of asymmetric and symmetric aNOTCH1 localization.\
(N and O) Day-3 DMSO-treated null ES colonies show strong AP staining all the way to the colony edge in (N). Treatment with 3 μM DAPT led to more differentiation in (O).\
(P--R) OCT4 is strongly expressed in day-4 DMSO-treated null ES cultures (P). With DAPT (Q,R), OCT4 expression is decreased.\
(S) Working model: In daughter cells that undergo differentiation, PRKCi can associate with PAR3 and PAR6. NUMB is recruited and directly phosphorylated. The activation of NUMB then leads to an inhibition in NOTCH1 activation and stimulation of a differentiation/maintenance program. In the absence of *Prkci*, the PAR3/PAR6 complex cannot assemble (although it may do so minimally with *Prkcz*). NUMB asymmetric localization and phosphorylation is reduced. Low levels of pNUMB are not sufficient to block NOTCH1 activation, and activated NOTCH1 preserves the stem cell self-renewal program. We suggest that PRKCi functions to drive differentiation by pushing the switch from an expansion phase that is symmetric to a differentiation and/or maintenance phase that is predominantly asymmetric. In situations of low or absent PRKCi, we propose that the expansion phase is prolonged.\
Scale bars, 50 μm in (A, B, F, G, H, I, J, J′, P--R); 200 μm in (A′ and B′); 25 μm in (C, C′, M, and M′); and 100 μm in (H′, I′, N, and O).\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Additional Inhibition of PRKCz Results in an Even Higher Percentage of OCT4-, SSEA1-, and STELLA-Positive Cells\
(A and A′) After day 4 without LIF, heterozygous ES cells undergo differentiation in the presence of Gö6983, while null ES cells stay as distinct colonies in (A′).\
(B and B′) Gö6983 stimulates an increase in OCT4+ populations in heterozygous EBs and an even larger OCT4+ population in null EBs in (B′, insets: green and red channels separately).\
(C--D′) An even higher percentage of cells are OCT4+ (C and C′) and SSEA1+ (D and D′) with Gö6983 treatment (day 12, three independent experiments).\
(E and F) More STELLA+ clusters containing a larger number of cells are present in drug-treated heterozygous EBs.\
(G and H) Null EBs also have more STELLA+ clusters and cells. Drug-treated null EBs exhibit a dramatic increase in the number of STELLA+ cells.\
(I--K) Some cells are double positive for STELLA and VASA in drug-treated null EBs (yellow arrows). There are also VASA-only (green arrows) and STELLA-only cells (red arrows) (three independent experiments).\
(L--P) Treatment with ZIP results in an increase in OCT4+ and STELLA+ cells. ZIP treatment also results in more cells that are VASA+ (three independent experiments); n = 11 for *Prkci*^*+/−*^, and n = 13 for *Prkci*^*+/−*^ + ZIP; n = 14 for *Prkci*^*−/−*^, and n = 20 for *Prkci*^*−/−*^ + ZIP; eight EBs assayed for both STELLA and VASA expression).\
Scale bars, 100 μm in (A and A′); 50 μm in (B and B′); and 25 μm in (E, I, and L).\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
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